Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 343

1.

Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations.

Hashim H, Abrams P.

Drugs. 2004;64(15):1643-56. Review.

PMID:
15257626
2.
3.

Overactive bladder in the elderly: a guide to pharmacological management.

Staskin DR.

Drugs Aging. 2005;22(12):1013-28. Review.

PMID:
16363885
4.

Solifenacin in the management of the overactive bladder syndrome.

Robinson D, Cardozo L.

Int J Clin Pract. 2005 Oct;59(10):1229-36. Review.

PMID:
16178992
5.

Muscarinic receptor antagonists for overactive bladder.

Abrams P, Andersson KE.

BJU Int. 2007 Nov;100(5):987-1006. Review.

6.

Diagnosis and treatment of the overactive bladder.

Wein AJ.

Urology. 2003 Nov;62(5 Suppl 2):20-7. Review.

PMID:
14662403
7.

Muscarinic receptor subtypes and management of the overactive bladder.

Chapple CR, Yamanishi T, Chess-Williams R.

Urology. 2002 Nov;60(5 Suppl 1):82-8; discussion 88-9. Review.

PMID:
12493364
8.

Overactive bladder treatments in early phase clinical trials.

Colli E, Digesu GA, Olivieri L.

Expert Opin Investig Drugs. 2007 Jul;16(7):999-1007. Review.

PMID:
17594185
9.

Antimuscarinics for the treatment of overactive bladder: current options and emerging therapies.

Hegde SS, Mammen M, Jasper JR.

Curr Opin Investig Drugs. 2004 Jan;5(1):40-9. Review.

PMID:
14983972
10.

Overactive bladder: an update.

Hashim H, Abrams P.

Curr Opin Urol. 2007 Jul;17(4):231-6. Review.

PMID:
17558264
11.

Darifenacin in the treatment of overactive bladder.

Parsons M, Robinson D, Cardozo L.

Int J Clin Pract. 2005 Jul;59(7):831-8. Review.

PMID:
15963212
12.

Solifenacin in overactive bladder syndrome.

Simpson D, Wagstaff AJ.

Drugs Aging. 2005;22(12):1061-9. Review.

PMID:
16363887
13.

[Changes in muscarinic receptors of the aging bladder].

Andersson KE, Schröder A.

Urologe A. 2004 May;43(5):552-6. Review. German.

PMID:
15098089
14.

Overactive bladder--a practical approach to evaluation and management.

Madersbacher H.

J Med Liban. 2004 Oct-Dec;52(4):220-6. Review.

PMID:
16432986
15.

Solifenacin succinate for the treatment of symptoms of overactive bladder.

Maniscalco M, Singh-Franco D, Wolowich WR, Torres-Colón R.

Clin Ther. 2006 Sep;28(9):1247-72. Review.

PMID:
17062299
16.
17.

Role of muscarinic receptor antagonists in urgency and nocturia.

Michel MC, de la Rosette JJ.

BJU Int. 2005 Sep;96 Suppl 1:37-42. Review.

18.

Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents.

Ohtake A, Saitoh C, Yuyama H, Ukai M, Okutsu H, Noguchi Y, Hatanaka T, Suzuki M, Sato S, Sasamata M, Miyata K.

Biol Pharm Bull. 2007 Jan;30(1):54-8.

19.

Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.

Garely AD, Lucente V, Vapnek J, Smith N.

Ann Pharmacother. 2007 Mar;41(3):391-8. Epub 2007 Mar 6.

PMID:
17341526
20.

Current and emerging investigational medical therapies for the treatment of overactive bladder.

Tiwari A, Naruganahalli KS.

Expert Opin Investig Drugs. 2006 Sep;15(9):1017-37. Review.

PMID:
16916270
Items per page

Supplemental Content

Write to the Help Desk